<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Champions Oncology Inc — News on 6ix</title>
<link>https://6ix.com/company/champions-oncology-inc</link>
<description>Latest news and press releases for Champions Oncology Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/champions-oncology-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683559b478dffbe2df0eb290.webp</url>
<title>Champions Oncology Inc</title>
<link>https://6ix.com/company/champions-oncology-inc</link>
</image>
<item>
<title>Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-names-brian-alexander-to-board-as-company-advances-data-driven-oncology-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-names-brian-alexander-to-board-as-company-advances-data-driven-oncology-strategy</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March</description>
</item>
<item>
<title>Champions Oncology Reports Revenue of $16.6 Million</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-revenue-of-dollar166-million</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-revenue-of-dollar166-million</guid>
<pubDate>Thu, 12 Mar 2026 20:01:00 GMT</pubDate>
<description>Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research ...</description>
</item>
<item>
<title>Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-to-announce-third-quarter-financial-results-on-thursday-march-12-2026-25</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-to-announce-third-quarter-financial-results-on-thursday-march-12-2026-25</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its</description>
</item>
<item>
<title>Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-quarterly-210000913</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-quarterly-210000913</guid>
<pubDate>Mon, 15 Dec 2025 21:00:00 GMT</pubDate>
<description>We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology ...</description>
</item>
<item>
<title>Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-second-quarter-210000581</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-second-quarter-210000581</guid>
<pubDate>Mon, 08 Dec 2025 21:00:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, ...</description>
</item>
<item>
<title>CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million</title>
<link>https://6ix.com/company/champions-oncology-inc/news/correction-champions-oncology-reports-quarterly-205000454</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/correction-champions-oncology-reports-quarterly-205000454</guid>
<pubDate>Mon, 15 Sep 2025 20:50:00 GMT</pubDate>
<description>This release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), ...</description>
</item>
<item>
<title>Champions Oncology Reports Record Quarterly Revenue of $14.0 Million</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-quarterly-195500380</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-quarterly-195500380</guid>
<pubDate>Mon, 15 Sep 2025 19:55:00 GMT</pubDate>
<description>Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its ...</description>
</item>
<item>
<title>Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-first-quarter-203000704</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-first-quarter-203000704</guid>
<pubDate>Wed, 10 Sep 2025 20:30:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results ...</description>
</item>
<item>
<title>Champions Oncology Reports Record Annual Revenue of $57 Million</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-annual-200000926</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-annual-200000926</guid>
<pubDate>Wed, 23 Jul 2025 20:00:00 GMT</pubDate>
<description>Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth ...</description>
</item>
<item>
<title>Champions Oncology Reports Record Annual Revenue of $57 Million </title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-annual-revenue-of-dollar57-million</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-annual-revenue-of-dollar57-million</guid>
<pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
<description>Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology</description>
</item>
<item>
<title>Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-fourth-quarter-123000636</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-fourth-quarter-123000636</guid>
<pubDate>Mon, 21 Jul 2025 12:30:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter ...</description>
</item>
<item>
<title>Champions Oncology Announces Appointment of New CEO</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announces-appointment-ceo-123000910</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announces-appointment-ceo-123000910</guid>
<pubDate>Fri, 18 Jul 2025 12:30:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed ...</description>
</item>
<item>
<title>Champions Oncology Announces Appointment of New CEO </title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announces-appointment-of-new-ceo</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announces-appointment-of-new-ceo</guid>
<pubDate>Fri, 18 Jul 2025 04:00:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in</description>
</item>
<item>
<title>Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-launches-radiopharmaceutical-services-123000255</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-launches-radiopharmaceutical-services-123000255</guid>
<pubDate>Tue, 08 Jul 2025 12:30:00 GMT</pubDate>
<description>Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational ...</description>
</item>
<item>
<title>Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-obtains-radioactive-materials-134500788</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-obtains-radioactive-materials-134500788</guid>
<pubDate>Mon, 28 Apr 2025 13:45:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing ...</description>
</item>
<item>
<title>Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncologys-data-platform-gains-120000104</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncologys-data-platform-gains-120000104</guid>
<pubDate>Thu, 24 Apr 2025 12:00:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of the world's first interpretable cell simulation ...</description>
</item>
<item>
<title>Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-quarterly-195500227</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-reports-record-quarterly-195500227</guid>
<pubDate>Tue, 11 Mar 2025 19:55:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third ...</description>
</item>
<item>
<title>Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-third-quarter-210000487</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announce-third-quarter-210000487</guid>
<pubDate>Thu, 06 Mar 2025 20:00:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for ...</description>
</item>
<item>
<title>Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announces-17-abstracts-140000313</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-announces-17-abstracts-140000313</guid>
<pubDate>Tue, 18 Feb 2025 14:00:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at ...</description>
</item>
<item>
<title>Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership</title>
<link>https://6ix.com/company/champions-oncology-inc/news/champions-oncology-enhances-clinical-bioanalytical-services-portfolio-with-new-technology-and-additional-leadership</link>
<guid isPermaLink="true">https://6ix.com/company/champions-oncology-inc/news/champions-oncology-enhances-clinical-bioanalytical-services-portfolio-with-new-technology-and-additional-leadership</guid>
<pubDate>Wed, 08 Jan 2025 05:00:00 GMT</pubDate>
<description>HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with</description>
</item>
</channel>
</rss>